Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CoA-S-trimethylene-acetyl-tryptamine is a synthetic organic compound listed in PubChem and DrugBank as a substance under research and development. Chemically, it is a conjugate involving Coenzyme A (CoA), a trimethylene linker, an acetyl group, and a tryptamine moiety. While specific clinical applications are not detailed, its structure suggests potential as an enzyme inhibitor. Research on similar CoASH-tryptamine adducts indicates they can act as potent bisubstrate inhibitors of enzymes such as Arylalkylamine N-acetyltransferase (AANAT), which plays a role in melatonin synthesis. This compound would likely function as a direct inhibitor of such enzymes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CoA-S-trimethylene-acetyl-tryptamine.